Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

(2014) Jason R. Westin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane–Induced Death by AS101 via Inhibition of the VLA-4–IL10–Survivin Axis

(2014) Hila Danoch et al.   MOLECULAR CANCER RESEARCH

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

(2014) Neil Desai et al.   Translational Oncology

Vinorelbine, Paclitaxel, Etoposide, Cisplatin, and Cytarabine (VTEPA) Is an Effective Second Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma

(2013) Rajni Sinha et al.   Clinical Lymphoma Myeloma & Leukemia

Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report

(2013) Liang Wang et al.   LEUKEMIA & LYMPHOMA

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

(2012) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes

(2011) P. P. Piccaluga et al.   BLOOD

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer

(2011) Huanjie Shao et al.   Journal of Thoracic Oncology

The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma

(2010) Chun-Te Chiang et al.   CANCER LETTERS

Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel

(2008) E. R. Gardner et al.   CLINICAL CANCER RESEARCH

SPARC in cancer biology: Its role in cancer progression and potential for therapy

(2008) Isabella T. Tai et al.   DRUG RESISTANCE UPDATES